vimarsana.com

Latest Breaking News On - Dual bispecific combination - Page 1 : vimarsana.com

Johnson & Johnson : Janssen Presents First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma

News Release Media Contact: Christie Corbett +1 857-636-0211 Satu Glawe +49 172-294-6264 Investor Relations: Raychel. | June 5, 2023

United statesArnob banerjeeSatu glaweChristie corbettYael cohenEuropean commissionNational comprehensive cancer networkEarly development oncologyAmerican society of clinical oncologyJanssen pharmaceutical companies of johnsonJanssen research developmentAviv sourasky medical centerHematology instituteNews releasePresents first ever resultsDual bispecific combination

vimarsana © 2020. All Rights Reserved.